Discovery of XL413, a potent and selective CDC7 inhibitor
about
Crystal structure of human CDC7 kinase in complex with its activator DBF4A high through-put screen for small molecules modulating MCM2 phosphorylation identifies Ryuvidine as an inducer of the DNA damage responseThe potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines and discovery of potential new DDK inhibitor scaffoldsDDK dependent regulation of TOP2A at centromeres revealed by a chemical genetics approachCDC7 inhibition blocks pathological TDP-43 phosphorylation and neurodegeneration.Regulation and roles of Cdc7 kinase under replication stress.Characterization of a Drosophila ortholog of the Cdc7 kinase: a role for Cdc7 in endoreplication independent of Chiffon.Cdc7 overexpression is an independent prognostic marker and a potential therapeutic target in colorectal cancer.Dbf4: the whole is greater than the sum of its partsCdc7-dependent and -independent phosphorylation of Claspin in the induction of the DNA replication checkpointCell division cycle 7-kinase inhibitor PHA-767491 hydrochloride suppresses glioblastoma growth and invasiveness.Reversal of DDK-Mediated MCM Phosphorylation by Rif1-PP1 Regulates Replication Initiation and Replisome Stability Independently of ATR/Chk1.Human RIF1 and protein phosphatase 1 stimulate DNA replication origin licensing but suppress origin activation.BRD4 facilitates replication stress-induced DNA damage response.DDK Has a Primary Role in Processing Stalled Replication Forks to Initiate Downstream Checkpoint Signaling
P2860
Q27682804-C257DECA-53DD-4F99-B120-1F82BA3D2E5AQ28539430-366D44F9-B8B9-4474-8E6E-623C14760826Q28545089-D19CEC7E-DC25-44BC-AF03-9E4C56A5CD27Q28822095-D1585D87-AA01-4B0D-B859-0A4538C2C53FQ30544943-9EB0049E-17BB-43EF-B229-88E91895F6B9Q33953075-0E8C17D8-7FB8-4C67-B642-EACDE9C2576AQ35121210-2ED50442-EBBF-4C64-85DE-86CCB85240CCQ35888823-D4EE9B05-3AB7-4C16-BCBF-A1CCA0F9AA6AQ36906226-55588735-73DA-418E-B0ED-0F94FF605CE3Q36923333-6CAF9FE9-7B52-43B5-B08C-2324CB0E8AF8Q38728647-2EDAE645-662B-46FF-BFB1-77811D21FB2AQ42136223-4A21D8B6-9E49-41D7-8A00-A8C4921B899FQ42319174-44C679E1-9F88-4A32-A9B3-CA7261B74B2EQ52595313-2C9CDAC5-B823-45B8-86B2-72EB658F4759Q57752857-1D22DD18-2D5B-4154-AD09-892A5AE0C4BE
P2860
Discovery of XL413, a potent and selective CDC7 inhibitor
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Discovery of XL413, a potent and selective CDC7 inhibitor
@ast
Discovery of XL413, a potent and selective CDC7 inhibitor
@en
Discovery of XL413, a potent and selective CDC7 inhibitor
@nl
type
label
Discovery of XL413, a potent and selective CDC7 inhibitor
@ast
Discovery of XL413, a potent and selective CDC7 inhibitor
@en
Discovery of XL413, a potent and selective CDC7 inhibitor
@nl
prefLabel
Discovery of XL413, a potent and selective CDC7 inhibitor
@ast
Discovery of XL413, a potent and selective CDC7 inhibitor
@en
Discovery of XL413, a potent and selective CDC7 inhibitor
@nl
P2093
P1476
Discovery of XL413, a potent and selective CDC7 inhibitor
@en
P2093
Adam Galan
Amy Lew Tsuhako
Arlyn Arcalas
Arthur Plonowski
Brian Kane
Cristiana A Zaharia
David Markby
David S Brown
Elena S Koltun
Gordon Stott
P304
P356
10.1016/J.BMCL.2012.04.024
P407
P577
2012-04-16T00:00:00Z